Free

This is a FREE video, please log in to watch it and claim CPD

Watch Now

To see members' videos, become a member today!

Join Us

Back to Video List

In association with IEL

The first licensed Ga-68 DOTA-peptide: technical aspects and clinical impact in PET imaging 16 May 2017

Significant changes have occurred with regards to the management of NET patients especially in molecular imaging and therapy. The video session will briefly touch upon the impact of technological developments in molecular imaging that have revolutionised NET clinical pathways. The presentation will then focus predominantly on the first licensed Ga-68 DOTA-peptide product in Europe and the production technology behind this development.

1 CPD credit.
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.

 

Duration:40 mins


Speaker info

Dr Prakash Manoharan

Dr Prakash Manoharan trained in medicine at the University of Bristol. He then undertook post graduate training in general medicine (MRCP) and radiology (FRCR). He is dually accredited in radiology and nuclear medicine with specialist cross sectional training in The Leeds Teaching Hospitals (CT, MRI,onco-radiology and nuclear medicine). After completing his USMLE, he undertook further accredited specialist training in The University of Michigan Health System, Ann Arbor, USA in molecular imaging, nuclear medicine and radionuclide targeted therapies. His sub specialised interest is in onco-radiology, neuroendocrine tumours and HPB oncology. He is a Consultant Radiologist and Nuclear Medicine Physician at The Christie, a role which commenced in January 2007. He is the deputy clinical lead of the ENETS centre of excellence at The Christie and the MRT lead for NET. In April 2016, he was appointed Academy Director at The Christie. This role includes providing clinical leadership in delivering PET CT service to 50% of the contracted work load of England. His research interest includes molecular and functional imaging looking at early biomarkers of response.

Mr José Calero

José Calero, BPharm, MSc, GPhC obtained his Bachelor of Pharmacy degree in 2005 from The University of Seville, Spain. During three years (2008-2011) of study he acquired theoretical and practical training in radiopharmacy at the University Hospital Virgen de Las Nieves in Granada, Spain. In the same time period, he earned his Master of Science degree in Medical Physics from the University of Granada (2010). In January 2012, Mr Calero started his professional career as a Radiopharmacist at The Christie NHS Foundation Trust in Manchester, United Kingdom. Since September 2012, Mr Calero has leaded The Christie Radiopharmacy as a Consultant Radiopharmacist and Head of Radiopharmacy. As of October 2014, Mr Calero became a member of the UK Radiopharmacy Group of experts.